NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Patient diagnosed as a chronic condition (angina pectoris, myocardial infarction and ischemic cerebrovascular disorder, etc., requiring prevention of thrombosis or embolism) that is taking the prescribed LDA continuously
Date of first enrollment	05/04/2010
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : D961H INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational material : Oral(capsule) 20mg, once daily for 72 weeks control material(s) Generic name etc : Placebo INN of investigational material : Therapeutic category code : --- Other Dosage and Administration for Investigational material : Oral(capsule) Placebo, once daily for 72 weeks

Outcome(s)

Primary Outcome	Frequency of gastric or duodenal ulcer
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	Not applicable
Gender	Both
Include criteria	1. Provision of written informed consent before starting the study-related procedures and examinations 2. Patients who have the history of gastric and/or duodenal ulcer 3. A diagnosis of a chronic condition (angina pectoris, myocardial infarction and ischemic cerebrovascular disorder, etc., requiring prevention of thrombosis or embolism) which requires taking the prescribed LDA during the study treatment period
Exclude criteria	1. Having gastric or duodenal ulcer (except for ulcer scar) 2. History of esophageal, gastric or duodenal surgery, except for simple closure of perforation